Rebecca Todd
Investment Director @ Longwall Venture
Harwell, United Kingdom
Rebecca Todd is a seed investor at Longwall Venture in Harwell focused on Biotechnology and Health Care. Rebecca Todd is the investment director of Longwall Venture Partners.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Rebecca Todd invests in
Stages Rebecca Todd invests in
Countries Rebecca Todd invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (43%)
- Health Care 2 (29%)
- Medical 1 (14%)
- Biopharma 1 (14%)
- Therapeutics 1 (14%)
Stage
- Seed 3 (43%)
- Series A 1 (14%)
- Venture - Series Unknown 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MicrofluidX is tackling the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy. | $4.3M / Seed / Dec 08, 2022 | ||
| MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies. | $4M / Seed / Dec 08, 2022 | ||
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.1M / Series A / Dec 14, 2020 | ||
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.2M / Venture - Series Unknown / Dec 14, 2020 | ||
| MicrofluidX is tackling the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy. | $1.8M / Seed / Apr 21, 2020 | ||
| MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies. | $1.7M / Seed / Apr 21, 2020 | ||
| Closed Loop Medicine is the global leader in the development of single prescription drug plus digital therapy (DTx) combination products developed to optimise dosing on an individual level with linked behaviour therapy to improve patient outcomes. The company was founded by an experienced team of healthcare professionals, entrepreneurs and lifescientists with experience of both drug and software development, as well as extensive health system innovation experience. The company has two products in development for hypertension and insomnia. It has further products in its pipeline for a wide portfolio of chronic diseases. The Company ensures that both patient and clinician are at the centre of its products design and development. | $2.8M / Seed / May 09, 2019 |
Co-Investors
About Longwall Venture
Longwall Ventures LLP is a venture capital firm specializing in growth capital, early stage, and start-up investments. It targets investing in science including physical science, life science, healthcare, security, media, business software, engineering, and technology companies based in United Kingdom. Longwall Ventures LLP was founded in 2011 and is based in Oxford, United Kingdom.
Longwall Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Denny
Partner
|
|||
Matthew Frohn
Partner
|
|||
|
Rebecca Todd
Investment Director
|
|||
Michael Penington
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rebecca Todd invest in?
Rebecca Todd invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Rebecca Todd?
Public channels for Rebecca Todd include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Rebecca Todd last invest?
The most recent investment recorded for Rebecca Todd closed in Dec 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
